Single therapeutic and supratherapeutic doses of corifollitropin alfa, a sustained follicle stimulant, do not prolong the QTcF-interval in healthy postmenopausal volunteers.

Science

First published in Int. Journal of Clinical Pharmacology and Therapeutics on 2015 Sep.
Int J Clin Pharmacol Ther. 2015 Sep;53(9):772-82. doi: 10.5414/CP202363.

Authors: de Kam PJ, van Kuijk JH, Zandvliet AS, Thomsen T

Download full article as Pdf file:

Pdf File

REACHING OUT IS EASY AND FAST – LET’S TALK

Prof. Dr. Thomas Forst

Chairman of the Executive Board

LET’S TALK SCIENCE

+49 621 150 45 – 0

Martin Mulder

Senior Vice President Corporate & Business Development

LET’S TALK BUSINESS

+49 621 150 45 – 0

Single therapeutic and supratherapeutic doses of corifollitropin alfa, a sustained follicle stimulant, do not prolong the QTcF-interval in healthy postmenopausal volunteers.

Read more

REACHING OUT IS EASY AND FAST – LET’S TALK

You May Also Like

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes

Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity: Data from two Phase I, randomised, placebo-controlled studies.

(Bersacapavir) In Participants With Moderate Hepatic Impairment.